Neuromedin U (rat)
Cat. No. 1917
Biological ActivityEndogenous peptide regulating blood pressure, ion transport in the gut, mesenteric blood flow and adrenocortical function. Also decreases food intake and body weight, increases body temperature and heat production, and inhibits gastric acid secretion via the CRH system following central administration in vivo.
(Modifications: Asn-23 = C-terminal amide)
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Mondal et al (2003) Neuromedin U acts in the cental nervous system to inhibit gastric acid secretion via CRH system. Am.J.Physiol.Gastrointest.Liver Physiol. 284 G963. PMID: 12584108.
Szekeres et al (2000) Neuromedin U is a potent agonist at the orphan G protein-coupled receptor FM3. J.Biol.Chem. 275 20247. PMID: 10811630.
Minamino et al (1985) Neuromedin U-8 and U-25: novel uterus stimulating and hypertensive peptides identified in porcine spinal cord. Biochem.Biophys.Res.Commun. 130 1078. PMID: 3841690.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Neuromedin U (rat) from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Neuromedin U (rat), supplier, NMU, Receptors, agonists, NeuromedinU, (rat), Tocris Bioscience, Neuromedin U Agonist products
Find multiple products by catalog number
New Products in this Area
Non-peptide apelin receptor agonistBML 111
FPR2 (lipoxin A4 receptor) agonistAmylin (rat)
Potent endogenous peptide agonist for amylin, calcitonin, CGRP and adrenomedullin receptorsCalcitonin (human)
Endogenous calcitonin receptor agonist; inhibits bone resorptionSpexin
Potent GAL2/3 agonist; exhibits anxiolytic effects in vivoMM 54
Potent apelin receptor antagonistMSG 606
Potent human MC1 receptor antagonist; also MC3 and MC5 partial agonist
April 1 - 5, 2017
Washington, D.C., USA